SCHEMBL5458911

SCHEMBL5458911

NC(=O)c1c(NC(=O)CO)sc2c1CCC(O)C2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AIP O00170 1/20 0.58
SGTA O43765 1/20 0.58
TOMM70 O94826 1/20 0.58
STIP1 P31948 1/20 0.58
PPP5C P53041 1/20 0.58
DNAJC7 Q99615 1/20 0.58
STUB1 Q9UNE7 1/20 0.58
PTPN1 P18031 1/20 0.56
MAPT P10636 4/20 0.53
DUSP3 P51452 1/20 0.53
PTPN5 P54829 1/20 0.53
PTPN11 Q06124 1/20 0.53
POLB P06746 1/20 0.52
FLT3 P36888 2/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPK1 P28482 1/20 0.51
ANO1 Q5XXA6 1/20 0.51
ALDH1A1 P00352 6/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455042 0.83 FLT3 (0.70) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5451302 0.83 FLT3 (0.70) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5449286 0.81 PTPN1 (0.55) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5453580 0.79 MAPT (0.56) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5453397 0.79 PTPN1 (0.53) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5454129 0.78 PTPN1 (0.52) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5446149 0.77 TNIK (0.74) PTPN1MAPTDUSP3PTPN5PTPN11
SCHEMBL5459994 0.77 TNIK (0.74) PTPN1MAPTDUSP3PTPN5PTPN11
SCHEMBL5752965 0.77 TNIK (0.74) PTPN1MAPTDUSP3PTPN5PTPN11
SCHEMBL5453345 0.76 TNIK (0.59) PTPN1MAPTDUSP3PTPN5PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 AIP 3230/4885SGTA 3685/4885TOMM70 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.